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RAD51 is the essential recombinase in the homologous 
recombination (HR) repair pathway, one of two cellular pathways 
that repair double-strand DNA (dsDNA) breaks 1. Upregulation 
of RAD51 is reported in several cancers, including triple-
negative breast cancer (TNBC) 2, glioblastoma 3, prostate cancer 
4
, and is a mechanism by which these tumors acquire resistance 
to therapies. HR-defective cells are significantly more sensitive 
to ionizing irradiation and DNA damaging chemotherapeutics 1. 
Since the pathway is predominantly utilized by actively 
replicating cells, short-term disruption of HR has little impact on 
quiescent cells of normal tissue, whilst being detrimental to 
rapidly proliferating cancer cells 1.  
RAD51 has been recognized as a potential oncotarget due to 
its critical role in HR, and contributes to an aggressive cellular 
phenotype and resistance to therapeutics. Several small molecule 
RAD51 inhibitors have been discovered by high-throughput 
screening of compound libraries, notably B02 5-7, the RI series 8-10 
and the IBR2 series 11,12 (Figure 1). Alternatively, a fragment-
based screening approach at Cambridge identified another series 
of compounds 13,14 (Figure 1). Mechanistically, B02 disrupts 
RAD51 binding to ssDNA, RI-1 interferes with RAD51 binding 
to dsDNA, and IBR2 and the Cambridge series inhibit RAD51-
BRCA2 interaction. These compounds have cytotoxic activity at 
micromolar concentrations. 
B02 was the first of these compounds to be well-profiled 7. 
DNA binding assays revealed that it disrupted initial RAD51 
binding to ssDNA, and later dsDNA binding to the RAD51-
ssDNA filament 7. A D-loop assay confirmed B02 specificity for 
human RAD51 over its bacterial homologue RecA and other 
human HR proteins15.  In vitro, B02 inhibited irradiation-induced 
RAD51 foci formation, HR repair of dsDNA breaks 7 and 
sensitized cells to a panel of chemotherapy drugs 5,7. In vivo B02 
significantly enhanced the therapeutic effect of cisplatin in a 
TNBC xenograft model5. The structure of B02 involves three 
chemically distinct components, which could be constructed and 
optimised through parallel approaches. Here we describe some 
structure-activity relationships for analogues of B02, leading to 
the discovery of an inhibitor selective for several human breast 
cancer cell lines including those expressing high RAD51. 
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RAD51 is a vital component of the homologous recombination DNA repair pathway and is 
overexpressed in drug-resistant cancers, including aggressive triple negative breast cancer 
(TNBC).  A proposed strategy for improving therapeutic outcomes for patients is through small 
molecule inhibition of RAD51, thereby sensitizing tumor cells to DNA damaging irradiation 
and/or chemotherapy.  Here we report structure-activity relationships for a library of
quinazolinone derivatives. A novel RAD51 inhibitor (17) displays up to 15-fold enhanced 
inhibition of cell growth in a panel of TNBC cell lines compared to compound B02, and
approximately 2-fold increased inhibition of irradiation-induced RAD51 foci formation. 
Additionally, compound 17 significantly inhibits TNBC cell sensitivity to DNA damage, 
implying a potentially targeted therapy for cancer treatment. 
2009 Elsevier Ltd. All rights reserved.
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Figure 1. Structurally different RAD51 inhibitors, including B02. 
Components of B02 to be varied in this study are separately colored. 
 
Several years ago, we developed a homology model of human 
RAD51, based on a full-length homologue from Pyrococcus 
furiosus (PDB code: 1PZN 16), to aid compound design. B02 was 
docked into the model in several different putative binding sites, 
including the ATPase domain known to bind small fragments like 
tetrapeptide and bicyclic aromatics 17.  One preferred 
conformation of B02 showed motif 2 (3-pyridyl) occupying the 
same cleft that accommodated aromatic groups, like the 
phenylalanine side chain of Phe-His-Thr-Ala (Figure 2). Motifs 1 
and 3 instead spread-eagled across the shallow hydrophobic 
entrance to the cleft with the charged residue D187 nearby. The 
cleft was surrounded by hydrophobic residues (L104, M158, 
I160, A190, A192, L203, A207, L219). A second shallow 
indentation close to motif 3, accommodating the threonine side 
chain of the tetrapeptide in the crystal structure with a truncated 
RAD51 17,  is formed by hydrophobic residues (F166, P168, 
L171, V185, L186, V189). These features were used to design 
our compound library in this report. 
 
Figure 2. Docking of B02 in the ATPase domain of a homology model of 
human RAD51.  
 
Ligands were synthesized, as shown in Scheme 1, to allow for 
independent optimisation of the three motifs (Scheme 1). Two 
general strategies were implemented, both involving the 
incorporation of motif 1 (R1) onto initial motif 3 (D to E, or H to 
I). The difference between early (A to B) or late (I to F) stages 
allowed incorporation of motif 2 (R2). The synthetic pathways 
were chosen so as to maintain the common intermediate as late as 
possible for structural diversification. To introduce motif 1  (R1 
in F), the common intermediate acid D (e.g. R2 = 3-pyridyl) was 
assembled by coupling ethyl anthranilate A with the 
corresponding acyl chloride, followed by ester hydrolysis. 
Depending on the availability of the building blocks, the 
cinnamide analogues (B) were also constructed by Heck coupling 
of the corresponding aromatic bromide with acrylamide C. After 
introducing motif 1 as an amine through amide coupling (D to 
E), the intermediates were cyclized under mild dehydration 
conditions with iodine and hexamethyldisilazine18 to give the 
desired quinazolinone products (F). In this way, one series of 
compounds incorporated alkyl and cycloalkyl substituents (1–8), 
and another series contained substituted aromatics with a variable 
spacer –(CH2)n–  (n =0-2, 9–27). The latter series was designed 
to optimally target residues F195 and Y191 through pi-
interactions. Various substituents, such as halogen, hydroxy, 
amino and its precursor nitro, carboxylate and acetamide were 
incorporated to improve properties or polar interactions.  
Motif 2 (R2 in F, R1 = 4-chlorobenzyl) was assembled using 
either a similar linear process (A to E to F), or more efficiently 
from common intermediate 2-methylquinazolinone I through 
one-step divergent enamine-aldehyde coupling (I to J to F).  A 
one-pot synthesis from anthranilic acid G to 2-
methylquinazolinone I, through the mixed anhydride 2-
methyloxazinone H, was used to prepare variations in Motif 3 
(R3). To probe the shallow hydrophobic cleft where threonine of 
Phe-His-Thr-Ala bound (Figure 2), one amino group was 
introduced at position 6 of the quinazolinone core (44), which 
was further derivatized by either acylation (45–51) or 
guanidinylation (52). 
The potency of ligands was assessed using immunofluorescent 
assay for their inhibition of DNA damage induced RAD51 foci 
formation (Figure 3), a critical property of RAD51 in HR. An 
initial modification at motif 1 (1–17) resulted in promising 
compounds, with both saturated cyclohexylmethyl (6) and 4-
chlorobenzyl (17) analogues displaying improved inhibition of 
RAD51 foci formation. One methylene spacer shorter (5 vs 6) or 
longer (10 vs B02) reduced the potency of RAD51 functional 
inhibition. Restricting rotation (indane 11) or introducing 
potential charged isosteres, such as morpholine (7–8) or pyridine 
to replace benzene (12–14), all reduced efficacy. Smaller alkanes 
(1–4) also displayed reduced activity. Varying spacer length in 
compound 17, with one methylene unit shorter (15) or longer 
(16), did not improve activity and indicated optimal positioning 
of the aromatic ring in 17. Of the substituted benzyl series, fluoro 
(18–20), nitro (21–22) and p-hydroxy (23) analogues showed 
comparable activity. A polar substrate, such as p-
acetamidomethyl (24) and carboxylic acid (25–26), were 
detrimental, while 3,4-dichloro (27) conferred a slight 
improvement. This demonstrated that a hydrophobic interaction 
was important at this site. 
Keeping motif 1 as 4-chlorobenzyl, any modifications at motif 
2 apart from 3-pyridyl were detrimental, including its 
regioisomer 4-pyridyl (36), mono-amino substituted 3-pyridyl 
(37–39), and a series of mono-substituted (hydoxy, nitro or 
amino) phenyl (28–35). This suggested that there were limits to 
both the substituent size and the polar interaction, with only the 
3-pyridyl moiety being effective at this site. 
 
  
 
 
 
Scheme 1. Synthetic analogues of B02 and their preparation. 
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Figure 3. Inhibition of RAD51 foci formation following irradiation 
induced DNA damage by representative compounds. (A) The ratio of 
RAD51 positive cells/ɣH2AX positive cells was quantified by IF in 
MDA-MB-231 cells following treatment with 10 µM of each compound 
and exposure to 6 Gy irradiation. (B) Representative images show that 17 
(10 µM) significantly inhibits DNA damage induced RAD51 foci 
formation with 6 Gy irradiation.  
 
In motif 3, incorporating an extended pi-system (40) or a 
nitrogen isostere (41–43) led to similar or increased cytotoxicity. 
In particular, the 6-aza quinazolinone analogue (43) produced the 
greatest cytotoxicity. Surface plasmon resonance (SPR) and 
further profiling in different assays indicated ligands 43, 48 and 
51 were non-selective binders of several proteins. Overall, 
compound 17, which elicited a favorable binding response 
representing 1:1 binding to RAD51 according to SPR, was 
notable for superior inhibition of DNA damage induced RAD51 
foci formation. 
Compound 17 was further investigated for sensitizing TNBC 
cell line MDA-MB-231 to irradiation. Combination of 17 and 
irradiation significantly reduced cell proliferation compared to 17 
alone (p<0.0005) or B02 combined with irradiation (p<0.05, 
Figure 4). Compared with B02 for growth inhibition in a panel of 
six TNBC cell lines with varying levels of RAD51 expression 
(Figure 5), compound 17 was more potent than B02 (IC50 ≤ 13.7 
µM vs ≤ 89.1 µM) across all TNBC cell lines assessed. The 
differing sensitivity of TNBC cell lines to RAD51 inhibition is 
likely influenced by specific mutations contained by each cell 
line and compensatory activity of alternate DNA repair pathways 
in response to RAD51 inhibition 19. We have previously shown 
that high RAD51 expressing MDA-MB-231 and MDA-MB-436 
cells are almost entirely reliant on the HR pathway and show 
minimal non-homologous end joining (NHEJ) activity when HR 
is disrupted by RAD51 inhibition. We showed correlation of 
RAD51 expression and IC50 in these cell lines. In contrast, high 
RAD51 expressing HCC1937 increases NHEJ activity when 
RAD51 is inhibited 19. We observed a slightly higher IC50 in this 
cell line.  These differing sensitivity profiles to RAD51 inhibition 
are reflected in the IC50 values and the corresponding dose-curves 
(Supporting Information Figure S1).  BT549 cells contain a 
PTEN mutation, which compromises HR activity 20, reflected by 
a gentler sloped dose curve in response to RAD51 inhibition. 
However, RAD51 inhibition was minimally toxic to normal 
breast epithelial cell line MCF10A which has unperturbed access 
to both HR and NHEJ repair pathways (IC50 ~ 48 µM, Table 1), 
suggesting a promising role in selectively inhibiting aggressive, 
metastatic breast cancer cells rather than normal cells. 
 
Figure 4. Effect of compound 17 on TNBC cell proliferation in 
combination with irradiation. (A) MDA-MB-231 cells were treated with 10 
µM of B02 or 17 +/- 6 Gy irradiation and proliferation measured over a time 
course of 120 h. The graph shows the mean % proliferation from 3 
independent experiments.  (B) Area under the curve (AUC) was calculated 
from proliferation data.  Treatment with 10 µM of 17 significantly sensitized 
cells to irradiation compared to no drug + irradiation (p<0.005), and was 
more highly significant than B02 plus irradiation (p<0.05). 
 
In conclusion, by altering the known RAD51 inhibitor B02, 
we have identified a new cinnamylquinazoline compound (17) 
that shows enhanced cytotoxicity via RAD51. 17 effectively 
inhibits both RAD51 foci formation, in response to DNA 
damage, and proliferation of TNBC cell lines. Most importantly 
17 sensitized aggressive metastatic TNBC to DNA damage 
induced by irradiation.  Our data supports the principle of 
targeting the HR pathway, specifically RAD51, as a mechanism 
to sensitize aggressive cancer to DNA damaging treatments. 
Compound 17 will serve as a valuable research tool for 
developing combination therapies to overcome RAD51 driven 
resistance and relapse in a variety of cancers.  
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Figure 5. (A) Western blot analysis showing RAD51 expression in whole 
cell extracts from TNBC cell lines used in proliferation assay. (B) Bar graph 
represents the average result (± SEM) of two experiments with RAD51 
expression normalised to MCF10A. 
 
Table 1. Comparison of IC50 values for B02 and compound 
17 in TNBC cell lines measured by MTS cell viability assay  
Cell Line IC50 ± SEM (µM) 
 B02 17 
MCF10Aa 47.7 ± 4.8 48.3 ± 4.8 
SUM159Tb 84.1 ± 1.6 5.5 ± 0.4 *** 
MDA-MB-468c 10.2 ± 0.5 5.7 ± 0.5 ** 
BT549d 35.4 ± 1.0 6.4 ± 0.7 ** 
Hs578te 9.6 ± 0.5 4.2 ± 0.5 * 
MDA-MB-231f 11.1 ± 0.4 6.7 ± 0.4 * 
MDA-MB-436g 5.7 ± 0.1 4.1 ± 0.1 ** 
HCC1937h 89.1 ± 5.7 13.7 ± 0.5 *** 
* p<0.05, **p<0.005 ***p<0.0005 based on two independent 
experiments. 
aNon-tumourigenic epithelial cell line, bInfiltrating ductal 
carcinoma, bAdenocarcinoma, cDuctal carcinoma, 
dCarcinoma, fAdenocarcinoma, gAdenocarcinoma, hDuctal 
carcinoma. 
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